ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Surveillance Colonoscopy Cost-Effective For High-Risk

July 30, 2010

Avastin-Zybrestat Combination Increases Progression-Free Survival in Phase II Trial

March 28, 2014

Abeloff Plans To Step Down As Cancer Center Director at Hopkins.

November 10, 2006

In Brief: New Mount Sinai Cancer Center Gets $7 Million; Jules Harris Named Rush Cancer Center Director

July 25, 1986

In Brief: Grants To Get Biggest Share Of NCI’s Extra $74 Million; A PR Failure In Pittsburgh

March 19, 1976

Youth Smoking Begins To Decline, NCI Says

April 5, 2002